Abstract
The success of a genetic study to understand the cause of mRNA vaccine-induced myocarditis or other rare adverse events is dependent on the patients and families who consent to participate. The article by Nishibayashi et al. in JoCI highlights the importance of reporting cases of rare and atypical responses to mRNA vaccines, particularly familial cases such as monochorionic diamniotic twins.
The authors also discussed the necessity to create an international registry of patients with vaccine-induced myocarditis. We hope that the article from Nishibayashi et al. and this commentary will inspire other teams of clinicians and scientists around the world to publish case reports of mRNA vaccine-induced myocarditis and refer their patients to an international consortium such as the COVID Human Genetic Effort to disentangle this mystery.